Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XL820 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| XL820 | DRUG | XL820 capsules administered orally as a single agent at a dose of 800 mg daily |
Inclusion Criteria: * Patients with metastatic or locally advanced or unresectable GIST who have intolerance of or disease progression following prior treatment with imatinib and/or sunitinib * ECOG (Eastern Cooperative Oncology Group) performance status ≤2 * Must have measurable disease per RECIST...
XL820 is an investigational small molecule being studied for the treatment of cancer, including gastrointestinal stromal tumors (GIST). It has been evaluated in clinical trials for adults with solid tumors and for advanced GIST resistant to imatinib and/or sunitinib.
XL820 is being developed by Exelixis, Inc., a biopharmaceutical company traded on NASDAQ under the ticker EXEL. The company has sponsored clinical trials of XL820 in the United States.
XL820 has completed Phase 1 and Phase 2 clinical trials. It is an investigational drug that has not been approved by the FDA, and it is no longer in active clinical development based on the completed trial statuses.
XL820 has been studied in three completed clinical trials: NCT00129571 and NCT00350831, both Phase 1 studies in adults with solid tumors, and NCT00570635, a Phase 2 study in adults with advanced GIST resistant to imatinib and/or sunitinib. All trials were conducted in the United States.
XL820 is the investigational name used by Exelixis for this compound. No alternative names have been reported in the clinical trial records, and it is distinct from other Exelixis drugs.